BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for MajorDepressive Disorder (MDD) in Adolescents Aged 15 to 21
false
áøééðñååéé áò"î
2
380
BRAINSWAY LTD
Corporation no:
513890764
10767
Israel Securities Authority
Tel Aviv Stock Exchange
C002
(
Public
)
Reported via MAGNA:
12/11/2025
www.isa.gov.il
www.tase.co.il
Reference:
2025-02-086585
Time of broadcast:
15:42
15:42
The corporation scheduled the publication of the report to
13/11/2025 13:00
Immediate Report
Regulation 4 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000
The corporation is a foreign private issuer as defined by U.S. Securities Laws.
Attached hereto is a report on
BrainsWay Receives FDA Clearance of Deep TMS™ as Adjunct Therapy for Major Depressive Disorder (MDD) in Adolescents Aged 15 to 21
BrainsWay_FDA_Clerance_for_Adolescent_MDD_isa.pdf
References of previous documents relating to this matter(the reference does not constitute incorporation by reference):
Stock Exchange/Market:
BWAY
Date of revision of form structure:
06/08/2024
Address:
äøèåí
19
,
éøåùìéí
91451
,
Tel:
02-5813140
,
Fax:
02-5812517
E-mail address:
uri@Brainsway.com
Company site:
www.Brainsway.com
Previous names of reporting entity:
Name of the Signatory:
Levy Hadar
Position of Signatory in the reporting corporation:
Chief Financial Officer
Name of Employer Company:
Address:
Hartum Street, Bynet Building
19
,
Jerusalem
9777518
Telephone:
97225824030
Facsimile:
97225812517
E-mail:
hadarl@brainsway.com
1